GO:1904321 response to forskolin: Genes and Methods

GO:1904321, response to forskolin, is a biological process term that captures any change in the state or activity of a cell or organism as a result of a forskolin stimulus. Forskolin is a naturally occurring diterpene widely used in biomedical research because it directly activates adenylyl cyclase, the enzyme that converts ATP to cyclic AMP (cAMP). Because cAMP is a central second messenger, forskolin treatment triggers a broad spectrum of cellular responses, including changes in enzyme activity, ion transport, secretion, gene expression and cell proliferation. The term is therefore relevant to researchers in neurobiology, cardiovascular biology, endocrinology and cancer biology who use forskolin as a pharmacological tool to probe cAMP-dependent pathways. The breadth of GO:1904321 is illustrated by studies across diverse organisms and tissues. In the turtle olfactory system, forskolin elicits responses that depend on Ca2+ and Cl- ions, linking the term to sensory transduction. In cardiac tissue, forskolin has been used to investigate beta-adrenoreceptor supersensitivity, highlighting its role in autonomic pharmacology. In renal physiology, forskolin stimulates hemodynamic responses in sheep, demonstrating developmental regulation of the response. In human disease contexts, intracavernosal forskolin has been explored for vasculogenic impotence, and forskolin synergizes with dexamethasone to induce myeloma cell death. These examples show that GO:1904321 is not a single linear pathway but a hub term encompassing context-dependent cAMP-mediated outcomes. For genomics and CRISPR researchers, GO:1904321 provides a framework for interrogating which genes are required for forskolin responsiveness. Adenylyl cyclase isoforms, G-protein subunits, phosphodiesterases, protein kinase A (PKA) subunits and downstream transcription factors all contribute to the response. Because forskolin sensitivity can be engineered by changing adenylyl cyclase isoform expression, the term is particularly amenable to knockout, point-mutation, knock-in and overexpression studies. This article reviews the definition, mechanism, key genes, disease links and research methods for GO:1904321, with a focus on how CRISPR-based cell models can accelerate discovery.

In our own words, GO:1904321 (response to forskolin) refers to any process that results in a change in the state or activity of a cell or an organism in terms of movement, secretion, enzyme production, gene expression, or other measurable outputs, as a result of a forskolin stimulus. The term is defined in the biological process aspect of the Gene Ontology and has no listed synonyms. It is a response-to-chemical term that sits downstream of forskolin's primary molecular action on adenylyl cyclase and encompasses all subsequent cellular and physiological changes.

GO:1904321 is important because forskolin is one of the most widely used pharmacological tools for activating cAMP signaling, and the term provides a standardized way to annotate and compare the resulting cellular responses across experiments. Because cAMP controls diverse processes such as cardiac contractility, renal hemodynamics, olfactory transduction, Schwann cell proliferation and cancer cell survival, understanding response to forskolin helps researchers interpret data from many physiological and pathological contexts. In the CRISPR era, the term also guides functional genomics screens that ask which genes are necessary or sufficient for forskolin responsiveness.

The following genes and proteins are central to the response to forskolin, based on their roles in cAMP signaling, adenylyl cyclase regulation, and downstream effector pathways.

The response to forskolin is regulated at multiple levels. Adenylyl cyclase isoform expression determines whether a cell is forskolin-sensitive or insensitive, as shown by the conversion of mouse-type IX adenylyl cyclase from forskolin-insensitive to forskolin-sensitive. Phosphodiesterases such as PDE4A and PDE4B degrade cAMP and thus limit the duration and magnitude of the response. G-protein subunits, including GNAS and GNAI1, modulate adenylyl cyclase activity and can influence forskolin responsiveness. In Schwann cells, the mitogenic response to forskolin is determined by pre-exposure to serum, time in vitro, and developmental age, indicating that the response is subject to context-dependent regulation. In skeletal muscle microvasculature, beta-adrenergic responsiveness is diminished after cardiac surgery, suggesting that physiological state regulates cAMP-mediated responses.

In multiple myeloma, forskolin synergizes with dexamethasone to induce cell death via BIM, a pro-apoptotic BCL-2 family member. This links GO:1904321 to cancer biology, where cAMP signaling can be exploited to overcome drug resistance. The synergy suggests that forskolin-sensitive pathways may be targeted therapeutically in hematological malignancies.

Forskolin has been used to investigate cardiac beta-adrenoreceptor supersensitivity, which is relevant to heart failure and arrhythmias. In renal physiology, forskolin stimulates hemodynamic responses in sheep, and these responses change with developmental age, which may inform pediatric renal pharmacology. In skeletal muscle microvasculature, beta-adrenergic responsiveness is diminished after cardiac surgery, a condition that may involve altered cAMP signaling.

Intracavernosal forskolin has been studied for the management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. This application directly links GO:1904321 to a human disease context, where cAMP-mediated smooth muscle relaxation is the therapeutic goal.

In the turtle olfactory system, forskolin elicits responses that depend on Ca2+ and Cl- ions, linking GO:1904321 to sensory transduction. In Schwann cells, forskolin influences mitogenic responses in a context-dependent manner, which is relevant to peripheral nerve regeneration and neuropathies.

Direct measurement of intracellular cAMP is the most proximal readout of GO:1904321. Forskolin is used to stimulate adenylyl cyclase, and cAMP levels are quantified using ELISA, luminescence-based assays, or FRET biosensors. These assays can distinguish forskolin-sensitive from forskolin-insensitive adenylyl cyclase isoforms and are compatible with CRISPR knockout or knock-in models.

RNA sequencing after forskolin treatment reveals gene expression changes that constitute part of the response to forskolin. In myeloma cells, forskolin-dexamethasone synergy leads to upregulation of BIM, which can be detected by RNA-seq. In Schwann cells, proliferative responses to forskolin imply activation of cell cycle genes that can be profiled by transcriptomics.

Because PKA and other kinases are activated downstream of cAMP, phosphoproteomics can identify substrates phosphorylated in response to forskolin. Kinase activity assays can measure PKA activity directly after forskolin stimulation, providing a functional readout of the response.

In systems where forskolin affects ion transport, such as the turtle olfactory system, electrophysiological or ion flux assays can measure Ca2+ and Cl- dependence of the response. In renal and cardiovascular studies, hemodynamic or smooth muscle relaxation assays provide physiological readouts of GO:1904321.

Researchers studying response to forskolin-related genes often need to determine whether a candidate gene is causally involved in cAMP signaling, ion transport, proliferation, or apoptosis. EDITGENE provides CRISPR-based cell model services that enable precise manipulation of genes in the GO:1904321 pathway, from knockout to knock-in and overexpression, supported by library screening and bioinformatics.

GO:1904321 (response to forskolin) is a broad biological process term that captures the many cellular and physiological changes triggered by forskolin, primarily through activation of adenylyl cyclase and elevation of cAMP. Its relevance spans sensory transduction, cardiovascular and renal physiology, cell proliferation, and cancer cell death. Understanding the genes and mechanisms underlying this response is essential for interpreting pharmacological experiments and for identifying therapeutic targets. CRISPR-based cell models, combined with cAMP assays, transcriptomics, and phosphoproteomics, provide powerful tools to dissect the response to forskolin and to discover new regulators.